3,887 reports of this reaction
1.3% of all ADALIMUMAB ADAZ reports
#18 most reported adverse reaction
PSORIATIC ARTHROPATHY is the #18 most commonly reported adverse reaction for ADALIMUMAB ADAZ, manufactured by Cordavis Limited. There are 3,887 FDA adverse event reports linking ADALIMUMAB ADAZ to PSORIATIC ARTHROPATHY. This represents approximately 1.3% of all 305,491 adverse event reports for this drug.
Patients taking ADALIMUMAB ADAZ who experience psoriatic arthropathy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PSORIATIC ARTHROPATHY is a less commonly reported adverse event for ADALIMUMAB ADAZ, but still significant enough to appear in the safety profile.
In addition to psoriatic arthropathy, the following adverse reactions have been reported for ADALIMUMAB ADAZ:
The following drugs have also been linked to psoriatic arthropathy in FDA adverse event reports:
PSORIATIC ARTHROPATHY has been reported as an adverse event in 3,887 FDA reports for ADALIMUMAB ADAZ. This does not prove causation, but indicates an association observed in post-market surveillance data.
PSORIATIC ARTHROPATHY accounts for approximately 1.3% of all adverse event reports for ADALIMUMAB ADAZ, making it a notable side effect.
If you experience psoriatic arthropathy while taking ADALIMUMAB ADAZ, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.